GordonMD Long Biased GP LLC 3
3 · Pyxis Oncology, Inc. · Filed Jul 10, 2026
Insider Transaction Report
Form 3
GordonMD Global Investments LP
10% Owner
Holdings
- 10,024,909(indirect: See footnote)
Common Stock, par value $0.001 per share
[F1] Common Stock Purchase Warrant
[F3][F2]Exercise: $3.29Exp: 2029-07-02→ Common Stock, par value $0.001 per share (4,900,039 underlying)
Footnotes (3)
- [F1]The securities to which this filing relates are held directly by GordonMD Long Biased Master Fund LP (the "Master Fund") to which GordonMD Global Investments LP (the "Investment Manager") serves as investment manager. Craig D. Gordon ("Mr. Gordon") is the managing member of GordonMD Long Biased GP LLC (the "GP"), the general partner of the Master Fund. Each of the Master Fund, the GP and Mr. Gordon disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.
- [F2]The Common Stock Purchase Warrant is exercisable on or after the earlier of (i) the date on which the Issuer first publicly discloses clinical data from its micvotabart pelidotin (MICVO) Phase 1 monotherapy study in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) and (ii) October 1, 2026.
- [F3]Exercise price of $3.289, subject to adjustments as set forth in the Common Stock Purchase Warrant.